U.S. optic neuritis Market - Industry Trends and Forecast to 2029
U.S. Optic Neuritis Market is projected to register a CAGR of 5.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation
U.S. Optic Neuritis Market, By Treatment (Corticosteroids, IV Immunoglobulin, Supplements, and Others), By Diagnosis (MRI Scan, Blood Tests, Occular Cohernce Tomography, Lumbar Puncture, and Others), By Route of Administration (Oral, Parenteral, and Others), By End User (Hospitals, Clinics, Academic Research Institutes, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the United States Optic Neuritis Market are:
• The rising healthcare expenditure and strategic initiatives by market players are giving opportunities to the Optic Neuritis market to enhance the treatments.
• An increase in the reprocessing of methodological advancements is enhancing the growth of the Optic Neuritis market.
Market Players
Some of the key market players for the United States Optic Neuritis Market are listed below:
• Pfizer Inc.
• Novartis AG
• Boehringer Ingelheim International GmbH
• Viatris, Inc.
• Bausch Health Companies, Inc.
• Bristol-Myers Squibb Company
• Fresenius Kabi USA
• ABBVIE
• Hikma
• Merck & Co.
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC.
• AdvaCare Pharma
• GSK plc
• Akorn Operating Company LLC
• Jubilant Cadista Pharmaceuticals Inc.
• Novitium Pharma
• OthersCompanies
• Pfizer Inc.
• Novartis AG
• Boehringer Ingelheim International GmbH
• Viatris, Inc.
• Bausch Health Companies, Inc.
• Bristol-Myers Squibb Company
• Fresenius Kabi USA
• ABBVIE
• Hikma
• Merck & Co.
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC.
• AdvaCare Pharma
• GSK plc
• Akorn Operating Company LLC
• Jubilant Cadista Pharmaceuticals Inc.
• Novitium Pharma
• Others
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of U.S. Optic Neuritis Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Treatment Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Market End User Coverage Grid
- 2.11 Vendor Share Analysis
- 2.12 Secondary Sources
- 2.13 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Pestel
- 4.2 Porter's Five Forces Model
- 5 Epidemiology
- 6 Industry Insights
- 6.1 Patent Analysis
- 6.2 Drug Treatment Rate By Matured Markets
- 6.3 Demographic Trends: Impacts On All Incidence Rates
- 6.4 Patient Flow Diagram
- 6.5 Key Pricing Strategies
- 6.6 Key Patient Enrollment Strategies
- 7 Pipeline Analysis
- 8 U.S. Optic Neuritis Market: Regulations
- 8.1 Regulation In The U.S.:
- 9 Market Overview
- 9.1 Drivers
- 9.1.1 Rising Prevalence Of Eye Disorders
- 9.1.2 Increase In Aging Population
- 9.1.3 Rise In Traumatic Injuries
- 9.2 Restraints
- 9.2.1 High Cost Associated With Optic Nerve Disorders Treatment
- 9.2.2 Risks Associated With Various Treatments Methods
- 9.3 Opportunities
- 9.3.1 Rise In Healthcare Expenditure
- 9.3.2 Strategic Initiatives Of Key Players
- 9.4 Challenges
- 9.4.1 Negative Effects Of Systemic Steroids
- 9.4.2 Lack Of Awareness Among People Regarding Different Eye Treatments
- 10 U.S. Optic Neuritis Market, By Treatment
- 10.1 Overview
- 10.2 Corticosteroids
- 10.2.1 Methylprednisolone
- 10.2.2 Prednisone
- 10.2.3 Others
- 10.3 Iv Immunoglobulin
- 10.4 Supplements
- 10.5 Others
- 11 U.S. Optic Neuritis Market, By Diagnosis
- 11.1 Overview
- 11.2 Mri Scan
- 11.3 Blood Test
- 11.4 Ocular Coherence Tomography
- 11.5 Lumbar Puncture
- 11.6 Others
- 12 U.S. Optic Neuritis Market, By Route Of Administration
- 12.1 Overview
- 12.2 Parenteral
- 12.3 Oral
- 13 U.S. Optic Neuritis Market, By End User
- 13.1 Overview
- 13.2 Hospitals
- 13.3 Clinics
- 13.4 Academic And Research Institutes
- 13.5 Others
- 14 U.S. Optic Neuritis Market, By Distribution Channel
- 14.1 Overview
- 14.2 Hospital Pharmacy
- 14.3 Retail Pharmacy
- 14.4 Others
- 15 U.S. Optic Neuritis Market: Company Landscape
- 15.1 Company Share Analysis: United States
- 16 Swot Analysis
- 17 Company Profile
- 17.1 Pfizer Inc.
- 17.1.1 Company Snapshot
- 17.1.2 Revenue Analysis
- 17.1.3 Product Portfolio
- 17.1.4 Recent Development
- 17.2 Novartis Ag
- 17.2.1 Company Snapshot
- 17.2.2 Revenue Analysis
- 17.2.3 Product Portfolio
- 17.2.4 Recent Development
- 17.3 Boehringer Ingelheim International Gmbh.
- 17.3.1 Company Snapshot
- 17.3.2 Revenue Analysis
- 17.3.3 Product Portfolio
- 17.3.4 Recent Development
- 17.4 Viatris Inc.
- 17.4.1 Company Snapshot
- 17.4.2 Revenue Analysis
- 17.4.3 Product Portfolio
- 17.4.4 Recent Development
- 17.5 Bausch & Lomb Incorporated
- 17.5.1 Company Snapshot
- 17.5.2 Revenue Analysis
- 17.5.3 Product Portfolio
- 17.5.4 Recent Developments
- 17.6 Bristol – Myers Squibb Company
- 17.6.1 Company Snapshot
- 17.6.2 Revenue Analysis
- 17.6.3 Product Portfolio
- 17.6.4 Recent Development
- 17.7 Fresenius Kabi Usa
- 17.7.1 Company Snapshot
- 17.7.2 Revenue Analysis
- 17.7.3 Product Portfolio
- 17.7.4 Recent Development
- 17.8 Abbvie Inc.
- 17.8.1 Company Snapshot
- 17.8.2 Revenue Analysis
- 17.8.3 Product Portfolio
- 17.8.4 Recent Development
- 17.9 Advacarepharma
- 17.9.1 Company Snapshot
- 17.9.2 Product Portfolio
- 17.9.3 Recent Development
- 17.10 Akorn Operating Company Llc.
- 17.10.1 Company Snapshot
- 17.10.2 Product Portfolio
- 17.10.3 Recent Development
- 17.11 Amneal Pharmaceuticals Llc
- 17.11.1 Company Snapshot
- 17.11.2 Revenue Analysis
- 17.11.3 Product Portfolio
- 17.11.4 Recent Development
- 17.12 Gsk Plc
- 17.12.1 Company Snapshot
- 17.12.2 Revenue Analysis
- 17.12.3 Product Portfolio
- 17.12.4 Recent Development
- 17.13 Hikma Pharmaceuticals Plc
- 17.13.1 Company Snapshot
- 17.13.2 Revenue Analysis
- 17.13.3 Product Portfolio
- 17.13.4 Recent Development
- 17.14 Jubilant Cadista
- 17.14.1 Company Snapshot
- 17.14.2 Product Portfolio
- 17.14.3 Recent Development
- 17.15 Merck & Co., Inc.
- 17.15.1 Company Snapshot
- 17.15.2 Revenue Analysis
- 17.15.3 Product Portfolio
- 17.15.4 Recent Developments
- 17.16 Novitium Pharma
- 17.16.1 Company Snapshot
- 17.16.2 Product Portfolio
- 17.16.3 Recent Development
- 17.17 Teva Pharmaceutical Industries Ltd.
- 17.17.1 Company Snapshot
- 17.17.2 Revenue Analysis
- 17.17.3 Product Portfolio
- 17.17.4 Recent Development
- 17.18 Accure Therepeutics
- 17.18.1 Company Snapshot
- 17.18.2 Product Portfolio
- 17.18.3 Recent Development
- 17.19 Acorda Therapeutics Inc.
- 17.19.1 Company Snapshot
- 17.19.2 Revenue Analysis
- 17.19.3 Product Portfolio
- 17.19.4 Recent Development
- 17.20 Biogen Inc.
- 17.20.1 Company Snapshot
- 17.20.2 Revenue Analysis
- 17.20.3 Product Portfolio
- 17.20.4 Recent Development
- 17.21 Mallinckrdot Pharmaceuticals
- 17.21.1 Company Snapshot
- 17.21.2 Revenue Analysis
- 17.21.3 Product Portfolio
- 17.21.4 Recent Development
- 17.22 Noveome Biotherapeutics, Inc.
- 17.22.1 Company Snapshot
- 17.22.2 Product Portfolio
- 17.22.3 Recent Development
- 17.23 Sanofi
- 17.23.1 Company Snapshot
- 17.23.2 Revenue Analysis
- 17.23.3 Product Portfolio
- 17.23.4 Recent Developments
- 18 Questionnaire
- 19 Related Reports 122
- List Of Tables
- Table 1 U.S. Optic Neuritis Market, Pipeline Analysis
- Table 2 U.S. Optic Neuritis Market, By Treatment, 2020-2029 (Usd Million)
- Table 3 U.S. Optic Neuritis Market, By Treatment, 2020-2029 (Volume In Million)
- Table 4 U.S. Corticosteroids In Optic Neuritis Market, By Treatment, 2020-2029 (Usd Million)
- Table 5 U.S. Optic Neuritis Market, By Diagnosis, 2020-2029 (Usd Million)
- Table 6 U.S. Optic Neuritis Market, By Route Of Administration, 2020-2029 (Usd Million)
- Table 7 U.S. Optic Neuritis Market, By End User, 2020-2029 (Usd Million)
- Table 8 U.S. Optic Neuritis Market, By Distribution Channel, 2020-2029 (Usd Million)
- List Of Figures
- Figure 1 U.S. Optic Neuritis Market: Segmentation
- Figure 2 U.S. Optic Neuritis Market: Data Triangulation
- Figure 3 U.S. Optic Neuritis Market: Droc Analysis
- Figure 4 U.S. Optic Neuritis Market: Global Vs Regional Market Analysis
- Figure 5 U.S. Optic Neuritis Market: Company Research Analysis
- Figure 6 U.S. Optic Neuritis Market: Interview Demographics
- Figure 7 U.S. Optic Neuritis Market: Dbmr Market Position Grid
- Figure 8 U.S. Optic Neuritis Market: Market End User Coverage Grid
- Figure 9 U.S. Optic Neuritis Market: Vendor Share Analysis
- Figure 10 U.S. Optic Neuritis Market: Segmentation
- Figure 11 The Increasing Prevalence Of Eye Disorders And Rise In The Geriatric Population Are Expected To Drive The U.S. Optic Neuritis Market In The Forecast Period Of 2022 To 2029
- Figure 12 Corticosteroids Segment Is Expected To Account For The Largest Share Of The U.S. Optic Neuritis Market In 2022 And 2029
- Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The U.S. Optic Neuritis Market
- Figure 14 U.S. Optic Neuritis Market: By Treatment, 2021
- Figure 15 U.S. Optic Neuritis Market: By Treatment, 2022-2029 (Usd Million)
- Figure 16 U.S. Optic Neuritis Market: By Treatment, Cagr (2022-2029)
- Figure 17 U.S. Optic Neuritis Market: By Treatment, Lifeline Curve
- Figure 18 U.S. Optic Neuritis Market: By Diagnosis, 2021
- Figure 19 U.S. Optic Neuritis Market: By Diagnosis, 2022-2029 (Usd Million)
- Figure 20 U.S. Optic Neuritis Market: By Diagnosis, Cagr (2022-2029)
- Figure 21 U.S. Optic Neuritis Market: By Diagnosis, Lifeline Curve
- Figure 22 U.S. Optic Neuritis Market: By Route Of Administration, 2021
- Figure 23 U.S. Optic Neuritis Market: By Route Of Administration, 2022-2029 (Usd Million)
- Figure 24 U.S. Optic Neuritis Market: By Route Of Administration, Cagr (2022-2029)
- Figure 25 U.S. Optic Neuritis Market: By Route Of Administration, Lifeline Curve
- Figure 26 U.S. Optic Neuritis Market: By End User, 2021
- Figure 27 U.S. Optic Neuritis Market: By End User, 2022-2029 (Usd Million)
- Figure 28 U.S. Optic Neuritis Market: By End User, Cagr (2022-2029)
- Figure 29 U.S. Optic Neuritis Market: By End User, Lifeline Curve
- Figure 30 U.S. Optic Neuritis Market: By Distribution Channel, 2021
- Figure 31 U.S. Optic Neuritis Market: By Distribution Channel, 2022-2029 (Usd Million)
- Figure 32 U.S. Optic Neuritis Market: By Distribution Channel, Cagr (2022-2029)
- Figure 33 U.S. Optic Neuritis Market: By Distribution Channel, Lifeline Curve
- Figure 34 U.S. Optic Neuritis Market: Company Share 2021 (%)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook